Actively Recruiting
CAR-T Followed by Bispecific Antibodies
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-03-18
42
Participants Needed
2
Research Sites
373 weeks
Total Duration
On this page
Sponsors
A
Abramson Cancer Center at Penn Medicine
Lead Sponsor
G
Genentech, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
CONDITIONS
Official Title
CAR-T Followed by Bispecific Antibodies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Life expectancy of at least 12 weeks
- History of relapsed or refractory large B-cell lymphoma, including transformed follicular lymphoma and follicular lymphoma Grade 3B
- Prior treatment with at least one anthracycline-containing regimen and one anti-CD20-directed therapy
- No available therapy expected to improve survival
- PET/CT, diagnostic CT, or MRI scan prior to CAR T-cell therapy showing at least one measurable lesion (≥1.5 cm nodal or ≥1 cm extra-nodal)
- PET/CT, diagnostic CT, or MRI scan showing measurable disease at least 30 days after CAR T-cell infusion and before study treatment
- At least 30 days have passed since CAR T-cell infusion at enrollment
- Adequate laboratory studies
- Ability and willingness to use proper contraceptive precautions
You will not qualify if you...
- Grade 3 or higher cytokine release syndrome after CAR T-cell therapy or unresolved CRS
- Grade 2 or higher neurological toxicity after CAR T-cell therapy or active neurological toxicity
- Inability to comply with hospitalization or activity restrictions
- Pregnant, lactating, or planning pregnancy during and shortly after study treatment
- Prior solid organ transplant
- History of autoimmune diseases such as myocarditis, autoimmune pneumonitis, myasthenia gravis, and others
- History of progressive multifocal leukoencephalopathy (PML)
- Severe allergic or anaphylactic reactions to monoclonal antibodies
- History of other malignancies affecting study compliance
- Significant cardiovascular disease (e.g., NYHA Class III/IV, recent myocardial infarction)
- Significant active pulmonary disease requiring oxygen or corticosteroids
- Active or recent major infections requiring IV antibiotics or hospitalization
- Recent major surgery within 4 weeks before study treatment
- Active or chronic infections increasing risk with bispecific antibody therapy
- Live attenuated vaccine within 4 weeks before study treatment
- Recent systemic immunosuppressive medications except low-dose corticosteroids
- History of drug or alcohol abuse within 12 months
- Any serious medical condition or lab abnormalities that prevent safe participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Actively Recruiting
2
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
R
Rachel Lundberg, PA-C
CONTACT
K
Kaitlin Kennard, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here